Phase III Study of ASP1941 - Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Combination With a Dipeptidyl Peptidase-4 Inhibitor in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control With a Dipeptidyl Peptidase-4 Inhibitor Alone
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Ipragliflozin (Primary) ; Alogliptin; Saxagliptin; Sitagliptin; Vildagliptin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Astellas Pharma
- 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 10 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 24 Nov 2010 New trial record